Business
DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of VONJO® (pacritinib)
DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sal...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n \n \n \n DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of VONJO® (pacritinib)\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n – Uncapped deal structure complements current VONJO royalty entitlement –\n \n \n \n \n – Now projecting Total Income CAGR at high end of our 7-9% guidance through 2025 and flat to slightly growing Total Income until 2030 –\n \n \n \n \n – The transaction extends DRI's overall portfolio duration to over 10 years –\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n July 7, 2023\n \n \n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the \"Trust\" or \"we\"), a global leader in providing financing to advance innovation in the life sciences industry, is pleased to announce that it has agreed to purchase of a royalty interest in the worldwide net sales of VONJO from S*Bio Pte Ltd for\n \n US$66 million\n \n .\n \n \n \n \n \n \n \n \n \n VONJO is an oral, small-molecule JAK2 inhibitor currently marketed by Swedish Orphan Biovitrum AB (\"Sobi\"), used for the treatment myelofibrosis (\"MF\") patients with severe thrombocytopenia. It was approved by the U.S. Food and Drug Administration (\"FDA\") in\n \n February 2022\n \n and is the only approved treatment for the indication.\n \n \n \"VONJO has addressed a significant unmet need in cytopenic MF patients and has seen an incredible uptake in its first year on the market,\" said\n \n Behzad Khosrowshahi\n \n , Chief Executive Officer of the Trust. \"We are excited to purchase a second royalty on this long duration, high-quality asset. This is the second royalty acquisition our team has completed in the past month and is a testament to our team's ability to execute on our unique pipeline opportunities. With this transaction, DRI Healthcare has now deployed\n \n US$636 million\n \n with an additional\n \n US$59 million\n \n in potential milestone payments since our IPO. With a pipeline of over\n \n US$2.5 billion\n \n in ...